OTCMKTS:NEPH - Nephros Stock Price, Forecast & News

Nephros' stock was trading at $7.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEPH shares have decreased by 13.0% and is now trading at $6.50. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nephros.

Nephros, Inc. (OTCMKTS:NEPH) issued its quarterly earnings results on Thursday, February, 27th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.09. The company had revenue of $3.16 million for the quarter. Nephros had a negative return on equity of 56.37% and a negative net margin of 49.93%. View Nephros' earnings history.

Nephros issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.5-15.5 million, compared to the consensus revenue estimate of $14.85 million.

3 brokerages have issued twelve-month price objectives for Nephros' shares. Their forecasts range from $16.00 to $16.00. On average, they anticipate Nephros' share price to reach $16.00 in the next year. This suggests a possible upside of 146.2% from the stock's current price. View analysts' price targets for Nephros.

Media coverage about NEPH stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nephros earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutNephros.

Some companies that are related to Nephros include Alphatec (ATEC), Iradimed (IRMD), SeaSpine (SPNE), Cytosorbents (CTSO), iCAD (ICAD), Westaim (WEDXF), Restoration Robotics (HAIR), Accuray (ARAY), Soliton (SOLY), Liquidia Technologies (LQDA), Apyx Medical (APYX), Pulse Biosciences (PLSE), Venus Concept (VERO), RenovaCare (RCAR) and BeyondAirInc . (XAIR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nephros investors own include Cytosorbents (CTSO), Iovance Biotherapeutics (IOVA), NovaBay Pharmaceuticals (NBY), Allena Pharmaceuticals (ALNA), BIOLINERX LTD/S (BLRX), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN), Exelixis (EXEL), Fate Therapeutics (FATE) and Amicus Therapeutics (FOLD).

Nephros trades on the OTCMKTS under the ticker symbol "NEPH."

Nephros' stock is owned by a variety of retail and institutional investors. Top institutional investors include Parkman Healthcare Partners LLC (2.48%), Ingalls & Snyder LLC (1.69%) and National Asset Management Inc. (0.18%). Company insiders that own Nephros stock include Andrew Astor, Daron Evans and Oliver J Spandow. View institutional ownership trends for Nephros.

NEPH stock was sold by a variety of institutional investors in the last quarter, including National Asset Management Inc.. View insider buying and selling activity for Nephros.

NEPH stock was acquired by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, and Ingalls & Snyder LLC. Company insiders that have bought Nephros stock in the last two years include Andrew Astor, Daron Evans, and Oliver J Spandow. View insider buying and selling activity for Nephros.

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NEPH stock can currently be purchased for approximately $6.50.

Nephros has a market capitalization of $58.55 million and generates $5.69 million in revenue each year. The company earns $-3,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Nephros employs 18 workers across the globe. View additional information about Nephros.

The official website for Nephros is http://www.nephros.com/.

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.